BioPharma Dive April 23, 2024
Giovanni Caforio, who left Bristol Myers last November, is set to succeed Novartis’ longtime chair Joerg Reinhardt next year.
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year.
Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025. The appointment of Caforio will be put to Novartis’ shareholders at the company’s annual general meeting. Announcement of the planned succession Tuesday came alongside first quarter earnings that beat Wall Street forecasts.
Caforio spent two decades at Bristol Myers, rising through the ranks...
Today's Sponsors
Today's Sponsor